Home » Newsletters » BioWorld Science

BioWorld Science

June 21, 2012

View Archived Issues

Novel therapeutic target for multiple sclerosis identified

Novel immunocytokine for rheumatoid arthritis shows promise in early-stage clinical trial

Universities team up to unveil new biomarker predicting TTR in colon cancer

Researchers at Leo Pharma synthesize novel CaSR agonists

Merck KGaA prepares novel protein kinase inhibitors

Spanish scientists develop new agents for neurodegenerative diseases

Alnylam product receives orphan drug status

Roche and Seaside Therapeutics to collaborate on treatments for neurodevelopmental disorders

New potassium channel blockers designed at Pierre Fabre

Japanese group patents novel DCP-LA enantiomers

Pharmacokinetics of pure icaritin investigated in rats

Janssen Pharmaceutica presents new matrix metalloproteinase inhibitors

Sirona Biochem reports findings on SGLT inhibitor in primates

FDA grants orphan drug status to new therapy for AML

RGN-259 improves severe dry eye in phase II trial

Biovest to seek approval for personalized NHL vaccine

NovaRx completes enrollment in pivotal Lucanix trial

Dosing begins in phase III MuDelta studies

Data monitoring committee recommends continued enrollment in Reolysin trial

FDA advisory committee votes on carfilzomib NDA

Biopump gets orphan drug status for hepatitis D

Pozen receives FDA response regarding PA-32540 bioequivalence study

Tetra Discovery Partners receives award from NIH

Medigene to advance optimized formulation of RhuDex

Otsuka and UCB Japan seek new approvals for antiepileptic drug

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...